Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole…

By H. Mouridsen, M. Gershanovich, Yan Sun, R. Pérez-Carrión, C. Boni, A. Monnier, J. Apffelstaedt, Robert Smith, H. Sleeboom, F. Jaenicke and 10 more. Journal of Clinical Oncology, 2003

739 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/63d16f3d96c3fcb76fd37849aad53f91789166b7

Citations in the corpus

• ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) (2014, neutral): “500 mg, every 4 weeks) [77–88].”